Prizloncabtagene Autoleucel

Preferred Label : Prizloncabtagene Autoleucel;

NCIt synonyms : Autologous CD19/CD20-targeting CAR T-cells EXP039; Autologous Anti-CD19/Anti-CD20 CAR T Cells EXP039; Autologous Anti-CD19/CD20 CAR-T Cells C-CAR039;

NCIt definition : A preparation of autologous T-lymphocytes engineered to express a second-generation chimeric antigen receptor (CAR) specific for the two tumor-associated antigens (TAAs) cluster of differentiation 19 (CD19) and CD20, with potential immunostimulating and antineoplastic activities. Upon administration, prizloncabtagene autoleucel targets and binds to CD19- and CD20-expressing tumor B-cells. This induces selective toxicity in tumor B-cells expressing these TAAs. Both CD19 and CD20 are B-cell-specific cell surface antigens overexpressed in B-cell lineage malignancies. Targeting both CD19 and CD20 may prevent tumor cell antigen escape and relapse.;

UNII : 35X9XB2HBG;

Molecule name : EXP-039; EXP 039; C CAR039; C-CAR039;

NCI Metathesaurus CUI : CL1648123;

Details

Origin ID

C178452;

UMLS CUI

C5706336;

Semantic type(s)
- Cell [UMLS semantic type]
chemical_or_drug_affects_cell_type_or_tissue
- Cytotoxic T-Lymphocyte [NCIt concept]
chemical_or_drug_has_mechanism_of_action
- Antigen Sensitization [NCIt concept]
chemical_or_drug_has_physiologic_effect
- Immunopotentiation [NCIt concept]
- T-Cell Activation [NCIt concept]
concept_is_in_subset
- CTRP Agent Terminology [NCIt concept]
- CTRP Terminology [NCIt concept]
- FDA Established Names and Unique Ingredient Identifier Codes Terminology [NCIt concept]
- GDC Terminology [NCIt concept]
- GDC Therapeutic Agent Terminology [NCIt concept]
- NCI Drug Dictionary Terminology [NCIt concept]
- NCIt Antineoplastic Agent Terminology [NCIt concept]
has_target
- B-Lymphocyte Antigen CD19 [NCIt concept]
- B-Lymphocyte Antigen CD20 [NCIt concept]

Keyword's position in hierarchy(ies) :

You can consult :

recommendations
documents concerning education
documents for patients